Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

Astrazeneca (AZN) reported $13.59 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.2%. EPS of $1.24 for the same period compares to $1.03 a year ago.The reported revenue represents a surprise of -0.66% over the Zacks Consensus Estimate of $13.68 billion. With the consensus EPS estimate being $1.10, the EPS surprise was +12.73%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Oncology- Tagrisso- U.S. $678 million compared to the $684.78 million average estimate based on three analysts. BioPharmaceuticals- CVRM- Farxiga- Established RoW: $120 million versus the three-analyst average estimate of $101.67 million. The reported number represents a year-over-year change of +11.1%. Oncology- Enhertu- Established RoW: $19 million versus the three-analyst average estimate of $21.59 million. The reported number represents a year-over-year change of +46.2%. Oncology- Enhertu- Europe: $43 million versus the three-analyst average estimate of $36.98 million. The reported number represents a year-over-year change of +65.4%. BioPharmaceuticals- R&I- Symbicort- World: $723 million versus the three-analyst average estimate of $772.02 million. BioPharmaceuticals- R&I- Pulmicort- World: $158 million compared to the $197.96 million average estimate based on three analysts. BioPharmaceuticals- CVRM- Crestor- World: $316 million compared to the $294.03 million average estimate based on three analysts. The reported number represents a change of +6.4% year over year. BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $161 million versus the three-analyst average estimate of $154.45 million. The reported number represents a year-over-year change of -2.4%. Oncology- Tagrisso- World: $1.68 billion compared to the $1.67 billion average estimate based on three analysts. The reported number represents a change of +5.3% year over year. BioPharmaceuticals- V&I- Synagis- World: $112 million versus the three-analyst average estimate of $132.88 million. The reported number represents a year-over-year change of -34.5%. BioPharmaceuticals- R&I- Fasenra- World: $418 million compared to the $379.51 million average estimate based on three analysts. BioPharmaceuticals- CVRM- Brilinta- World: $305 million versus the three-analyst average estimate of $263.03 million. The reported number represents a year-over-year change of -5.6%. View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have returned -4.9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks